loader from loading.io

The Basics of Critical Access Hospitals (CAHs)

Pharmacy Revenue Cycle Podcast

Release Date: 11/29/2021

The Heavy Hitters for July Quarterly Updates show art The Heavy Hitters for July Quarterly Updates

Pharmacy Revenue Cycle Podcast

July 2023 is here and time to validate another round of quarterly updates from CMS. The JZ modifier, in addition to the JW modifier, is now required to effectively bill for drug waste (JW) and to attest when no drug was discarded (JZ) for all separately payable that are single-dose or single-use containers. Additionally, we have updated the Visante Quarterly Update Tool and the C9399 Tool to help organizations validate that their system is up to date with the recent changes.  

info_outline
Beat Inflation with a Part B Rebate  show art Beat Inflation with a Part B Rebate

Pharmacy Revenue Cycle Podcast

As a part of the Inflation Reduction Act of 2022, CMS is requiring manufacture rebates for certain Medicare Part B drugs in which the cost has exceeded inflation. Beneficiaries out of pocket costs will be reduced to 20% of the inflation-adjusted payment described in the Act.

info_outline
Don’t be “SAD”... An Alternative Way to Handle Self-Administered Drugs  show art Don’t be “SAD”... An Alternative Way to Handle Self-Administered Drugs

Pharmacy Revenue Cycle Podcast

Self-administered drugs (SAD) have been a long-standing controversy when administered in a hospital outpatient setting from the perspectives of a patient, frontline healthcare workers, and billing. “Why does my Tylenol cost $10 per tablet, but the 1,000-count bottle I have at home was purchased for $3?” This question is often difficult to answer and may lead to unintended operational consequences.  

info_outline
Botulinum toxin PA – Are you exempt? show art Botulinum toxin PA – Are you exempt?

Pharmacy Revenue Cycle Podcast

The new year brings a new focus on resolutions including prior authorization processes. In July 2020, Medicare implemented a prior authorization process for select services including botulinum toxin. Its time to revisit workflow processes and, if not exempt, confirm with respective teams that a prior authorization is obtained prior to providing the service.

info_outline
Designer HCPCS Codes are in the Mainstream Spotlight  show art Designer HCPCS Codes are in the Mainstream Spotlight

Pharmacy Revenue Cycle Podcast

The Pharmacy Revenue Cycle is starting out with a new fashion design for 2023 as there are 36 new brand-specific HCPCS codes. CMS has been reviewing its approach for assigning for drugs that have been approved under the Food, Drug and Cosmetic Act 505(b)(2) New Drug Application (NDA) or the Biologics License Application (BLA) after October 2003. These drugs are not rated therapeutically equivalent to the reference drug listed in the FDA’s Orange Book and therefore are considered single-source products according to section 1847A(c)(6) of the Social Security Act. Each single source product...

info_outline
Hospital Outpatient Prospective Payment System (OPPS) Final Rule- CY2023 show art Hospital Outpatient Prospective Payment System (OPPS) Final Rule- CY2023

Pharmacy Revenue Cycle Podcast

The Centers for Medicare & Medicaid Services (CMS) provided the OPPS Final Rule for CY2023 in the Federal Register on Provisions in this rule will be effective for dates of service on or after January 1, 2023. Significant changes for drug reimbursement and coding occur in three areas: 340B-acquired drugs, non-opioid pain management reimbursement in Ambulatory Surgery Centers (ASC) and Hospital Outpatient Departments (HOPD), and new requirements for reporting waste in HOPD. 340B-acquired Drugs In light of the Supreme Court decision in American Hospital Association v. Becerra, 142 S. Ct....

info_outline
Drug Waste is Packed with a Punch and a Refund show art Drug Waste is Packed with a Punch and a Refund

Pharmacy Revenue Cycle Podcast

Dive into the CY23 CMS Physician Fee Schedule rule as it relates to the new requirements for discarded drugs or drug waste. A JW and JZ modifier are required for all Part B separately payable single-dose or single-use packages. Additionally, manufacturers are required to pay a refund for discarded drugs that exceed 10% of the total charges. 

info_outline
Payment Increases for Biosimilars show art Payment Increases for Biosimilars

Pharmacy Revenue Cycle Podcast

Payment Increases for Biosimilars On April 16th, 2022, the Inflation Reduction Act of 2022 was signed into law. Section 11403 requires a temporary increase in add-on payment for qualifying biosimilars from 6% to 8% for 5 years. This change was implemented on October 1, 2022, and CMS uploaded pricing files that already include the temporary price increase. Applicable 5-year period This increase began on October 1, 2022, for products for which payment was made by September 30, 2022. For other biosimilar products in which payment was made between October 1, 2022 - December 31, 2027, the 5-year...

info_outline
Car T-cell Therapy: Coverage and Billing-Outpatient (Updated – October 1, 2022) show art Car T-cell Therapy: Coverage and Billing-Outpatient (Updated – October 1, 2022)

Pharmacy Revenue Cycle Podcast

Chimeric Antigen Receptor (CAR) T-cell therapy is an example of a rapidly emerging immunotherapy approach called adoptive cell transfer (ACT) where patients’ own immune cells are collected and used to treat their cancer. This newsletter details coverage and billing instructions when the products are used on an outpatient basis and has been updated to reflect HCPCS codes current as of October 1, 2022. The Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) regulates cellular therapy products, human gene therapy products, and certain devices related to...

info_outline
Vacating the 340B Payment Reduction Policy show art Vacating the 340B Payment Reduction Policy

Pharmacy Revenue Cycle Podcast

On September 28, 2022, the US District Court issued a that states the Department of Health and Human Services (HHS) is required to vacate the prospective portion of the 340B reimbursement rate outlined in the 2022 Outpatient Prospective Payment System (OPPS) Rule. In other words, payment rates must revert to the default of ASP + 6% rather than the reduced rate for select drugs of ASP - 22.5%. The decision was determined to not cause substantial disruption; thereby, requiring HHS to begin immediately. This was in response to American Hospital Association v. Becerra, 142 S. Ct. 1896 (2022), in...

info_outline
 
More Episodes

A reader inquired about Critical Access Hospitals (CAH), so we have put together a few items that pertain to the intricacies of CAHs and how they differ from the Hospital Outpatient/Inpatient Departments. 

 

CAH are located in rural areas of a State that has established a Medicare rural hospital flexibility program, or located in a Metropolitan Statistical Area (MSA) that is treated as being located in a rural area based on law or regulation of the State. It is required to be more than a 35-mile drive from any other hospital or “necessary provider”. If located in mountainous terrain or areas with only secondary roads, the CAH is only required to be 15 miles from another necessary provider. Additional eligibility criteria include: 

  • Must provide 24-hour emergency care

  • No more than 25 beds for acute inpatient care or skilled nursing facility swing beds

  • Maintain an annual average length of stay of no longer than 96 hours

  • Must be certified by CMS and required to meet the conditions of participations for CAH

     

The first call out pertaining to CAH, is they are not reimbursed utilizing the inpatient prospective payment system (IPPS) or the outpatient prospective payment system (OPPS). The following reimbursement rules do not apply:

  • The lesser of cost or charges rule

  • Ceilings on hospital operating costs

  • The reasonable compensation equivalent limits for physician services to hospitals 

  • 1- and 3- day payment window provisions. In other words, outpatient services provided within the 1- and 3- day payment window will continue to be paid as an outpatient service rather than bundled on the inpatient claim.

 

Inpatient payment is based upon 101% of reasonable cost or some MACs may pay on a per diem rate. Outpatient payment can be made using one of two methods. Method I (standard option) in which professional services are billed to Part B and reimbursement is 101% of reasonable cost less the deductible and coinsurance amounts. CAHs have the option to elect an alternative payment method or Method II (optional) when professional services are billed to Part A. Payment is the sum of the 101% of the reasonable cost of the facility services and 115% of the Medicare Physician Fee Schedule (MPFS) for professional services, less any deductible or coinsurance. Refer to the respective MAC regarding billing guidance. 

 

CAH, while generally 340B eligible, are not required to report the TB or JG modifiers as we have discussed in a previous newsletter. CAH are not subject to regulations of the HOPPS; thus, regardless of payment methods chosen, they are not subject to the ASP reduction. 

 

Shout Outs!

  1. Health systems big or small should understand the differences and regulations when billing CAH from other hospital or physician departments. 

 

Our goal is simple; we’re taking complex information and making it practical. 

Until our next edition, this is Maxie Friemel and Agatha Nolen providing you with tips for increasing your Pharmacy Revenue.